We thank Nahmod et al 1 for their interest in our studies and for their intriguing experiments with dendritic cells that corroborate and complement our findings. One limitation of the bone marrow transfer strategy is that this approach does not elucidate which specific mononuclear cell populations are mediating blood pressure elevation and/or tissue damage. Therefore, experiments like those conducted by Nahmod et al 1 will be crucial in defining the precise roles of angiotensin II type 1 (AT 1 ) receptors on individual immune cell lineages in regulating inflammation. Reconciling the results of the diverse studies exploring the functions of AT 1 receptors on immune cells is indeed challenging, but the divergent outcomes may accrue in part from the characteristics of the injury models used in these studies. For example, although AT 1A deficiency was indeed detrimental in our model of autoimmune glomerulonephritis, we were not able to demonstrate a role for AT 1 receptors on immune cells in that model, because AT 1A receptor-deficient bone marrow chimeras had similar kidney injury to controls. 2 Rather, we posited that glomerular AT 1b receptors activated by high levels of angiotensin II in the AT 1A receptor-deficient mice caused the exaggerated glomerular injury, because losartan therapy was protective in these animals. By contrast, in a model of antibody-mediated nephritis, Hisada et al 3 found reduced kidney injury in AT 1A receptor-deficient mice and in a follow-up study were able to demonstrate that AT 1A receptors in a nonhematopoietic cell lineage were likely responsible for the AT 1A -mediated kidney injury in their original study. This lack of a role for AT 1A on immune cells in antibody-mediated disease is consistent with the finding of Guzik et al 4 that B lymphocytes, which produce antibody, do not play a demonstrable role in the pathogenesis of angiotensin II-dependent hypertension. Therefore, we have focused on AT 1 receptors in immune cell lineages that are involved in cell-mediated immunity, which include T lymphocytes, macrophages, and dendritic cells. Together, studies published to date suggest the curious paradox that AT 1 receptors on immune cells play a more transparent role in nonimmune kidney disease (ie, associated with hypertension) than in immunemediated kidney diseases. In addition to differences in injury models, discrepant reports regarding expression of angiotensin receptor isoforms on immune cell lineages greatly impact the interpretation of the studies in this field. For example, we have been unable to implicate the AT 1b or the AT 2 receptor in immune cell signaling because we cannot detect expression for these isoforms in T lymphocytes or macrophages using our RT-PCR primers (data not shown). By contrast, other groups using their own primers have found expression of both AT 1b and AT 2 receptors in mononuclear cell populations. 5,6 Despite all of these discordant results, we are encouraged that the role of the renin-angiotensin system in regulating immune responses is now receiving considerable attention. Accordingly, careful and collective review of the growing number of studies including those conducted by Nahmod et al 1 will undoubtedly lead to a clearer understanding of how AT 1 receptors on immune cells impact the progression of kidney disease.
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